Suggested remit: To appraise the clinical and cost effectiveness of tanezumab within its marketing authorisation for treating moderate to severe chronic pain caused by osteoarthritis.
Status Proposed
Process STA 2018
ID number 1603

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
03 August 2020 - 01 September 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance